Eupraxia Pharmaceuticals Inc. Files September 2025 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Oct 1, 2025 · CIK: 1581178
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, pharmaceuticals
TL;DR
Eupraxia Pharma (EPRX) filed its monthly 6-K for Sept 2025. Standard update.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 1, 2025, for the month of September 2025. The company, incorporated in Canada with its principal executive office in Victoria, British Columbia, is reporting under the Securities Exchange Act of 1934. Eupraxia Pharmaceuticals Inc. is classified under Pharmaceutical Preparations.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Eupraxia Pharmaceuticals Inc.'s activities during September 2025.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) that typically contains periodic operational or financial information and does not indicate significant new risks.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- 001-41923 (company) — SEC File Number
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (company) — Principal Executive Office Address
- 2834 (company) — Standard Industrial Classification Code
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the issuer would be required to disclose to its home country security holders.
What period does this specific Form 6-K cover?
This Form 6-K is for the month of September 2025.
What is Eupraxia Pharmaceuticals Inc.'s Standard Industrial Classification (SIC) code?
Eupraxia Pharmaceuticals Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Eupraxia Pharmaceuticals Inc. headquartered?
Eupraxia Pharmaceuticals Inc.'s principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Is Eupraxia Pharmaceuticals Inc. filing a Form 20-F or Form 40-F?
The filing indicates that Eupraxia Pharmaceuticals Inc. is submitting a Form 40-F.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-10-01 10:56:41
Filing Documents
- f6k_100125.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 18KB
- 0001171843-25-006215.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EUPRAXIA PHARMACEUTICALS INC. Date: September 29, 2025 By: /s/ Alex Rothwell Name: Alex Rothwell Title: Chief Financial Officer